Investing

Allergan, Newell Brands Topple into Thursday's 52-Week Low Club

October 19, 2017: Here are four stocks trading with heavy volume among 13 equities making new 52-week lows in Thursday’s session. On the NYSE, decliners led advancers by about 8 to 7 and on the Nasdaq decliners led advancers by about 3 to 2.

Allergan plc (NYSE: AGN) dropped about 3.2% Thursday to post a new 52-week low of $182.80 after closing at $187.15 on Wednesday. The 52-week high is $256.80. Volume was around 86.5 million, more than double the daily average of about 2.6 million. The company’s blockbuster eye drug may see a generic competitor as early as next year.

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) dropped about 64% Thursday to post a new 52-week low of $0.88 after closing at $1.52 on Wednesday. The 52-week high is $5.02. Volume was around 5.7 million, approaching six times the daily average. The company priced a convertible offering this morning at $1.10 per share, making investors very unhappy.

Newell Brands Inc. (NYSE: NWL) dropped about 1.9% Thursday to post a new 52-week low of $40.44 after closing at $41.21 on Wednesday. The stock’s 52-week high is $55.08. Volume of around 5.2 million was about 15% above the daily average. The company had no specific news.

Sally Beauty Holdings Inc. (NYSE: SBH) posted a new 52-week low of $16.36 on Thursday, down about 7.8% from Wednesday’s closing price of $17.75. The stock’s 52-week high is $30.17. Volume totaled around 5 million shares, more than double the daily average. The company had no specific news.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.